| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
CRBN (cereblon), a substrate receptor for the CRL4 E3 ubiquitin ligase complex.
|
|---|---|
| ln Vitro |
Cereblon inhibitor 2 is an effective inhibitor of the cereblon protein. Its in vitro activity is characterized by its ability to bind to cereblon and inhibit its function as a substrate receptor, thereby disrupting the degradation of certain proteins regulated by the CRL4CRBN E3 ubiquitin ligase complex. Unlike PROTACs, which leverage cereblon to degrade target proteins, this inhibitor blocks cereblon activity. It is useful in solid tumor research, especially breast cancer, where modulation of cereblon-mediated degradation may have therapeutic implications. The specific DC50 or IC50 values for this compound have not been widely reported in public literature, but it is a tool for studying the role of cereblon in cancer biology.
|
| ln Vivo |
No specific in vivo activity has been widely reported for cereblon inhibitor 2; however, as an inhibitor of cereblon, it is expected to have in vivo effects in animal models of solid tumors, particularly breast cancer. Preclinical studies suggest it may have potential in treating cancers where cereblon dysregulation contributes to disease progression. Further in vivo studies are ongoing for this research compound.
|
| Enzyme Assay |
The binding affinity of cereblon inhibitor 2 to the cereblon protein is typically determined using biophysical methods such as surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). Alternatively, cellular assays measuring the activity of cereblon-dependent degradation pathways can be used to assess its inhibitory activity. The purity of the compound is typically confirmed by HPLC, with a standard purity of >98%.
|
| Cell Assay |
The in vitro activity of cereblon inhibitor 2 is evaluated in cereblon-expressing cancer cell lines, such as breast cancer cells. Cells are treated with increasing concentrations of the compound (e.g., 1 nM to 10 uM) for a defined period, typically 4-24 hours. After treatment, the levels of proteins known to be regulated by cereblon (e.g., IKZF1, IKZF3) are measured by Western blotting or quantitative proteomics to assess the inhibitory effect of the compound on cereblon-mediated degradation. Cell viability assays (e.g., MTT or CellTiter-Glo) can also be performed to evaluate the anti-proliferative effects of the compound.
|
| Animal Protocol |
In vivo efficacy studies for cereblon inhibitor 2 would typically be conducted in mouse xenograft models of solid tumors, especially breast cancer. The compound would be formulated in a suitable vehicle (e.g., 10% DMSO, 40% PEG300, 5% Tween-80, 45% saline) and administered via oral gavage, intraperitoneal (IP), or intravenous (IV) injection. Tumor growth inhibition, modulation of cereblon-regulated protein levels in tumor tissue, and overall animal health would be monitored. The compound is useful for studying the in vivo role of cereblon in cancer progression.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 440.88, a molecular formula of C22H21ClN4O4, and a purity of >98% (HPLC). It appears as a solid powder. Solubility: DMSO: 200 mg/mL (453.64 mM; need ultrasonic). For storage, it should be kept as a powder at -20degC for up to 3 years or at 4degC for up to 2 years. In a solvent, it can be stored at -80degC for 6 months or at -20degC for 1 month. The product should be stored under recommended storage conditions; information concerning product stability, particularly in solution, has rarely been reported and in most cases only a general guide can be offered.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human therapeutic or clinical applications. Standard chemical safety precautions should be followed during handling. The product has not been fully validated for medical applications. It is not an approved drug and is intended for laboratory research use only. Information concerning product stability, particularly in solution, has rarely been reported.
|
| References | |
| Additional Infomation |
Cereblon inhibitor 2 is a valuable tool compound for studying the role of cereblon in protein homeostasis and cancer biology. Unlike PROTACs, which use cereblon as a tool to degrade target proteins, this inhibitor allows researchers to block cereblon function and observe the downstream effects on protein degradation pathways. This compound has been described in patent US20220242846A1 and is useful for studying the therapeutic potential of targeting cereblon in solid tumors, including breast cancer. It serves as a chemical probe to dissect the molecular mechanisms of cereblon-mediated substrate recognition and degradation.
|
| Exact Mass |
440.125
|
|---|---|
| CAS # |
2639380-62-2
|
| PubChem CID |
156271380
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
31
|
| Complexity |
747
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C=C(C=C1)NC(=O)NCC2=CC3=C(CN(C3=O)C4CCC(=O)NC4=O)C=C2)Cl
|
| InChi Key |
JZFGEKDBVDHOTP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H21ClN4O4/c1-12-2-5-15(9-17(12)23)25-22(31)24-10-13-3-4-14-11-27(21(30)16(14)8-13)18-6-7-19(28)26-20(18)29/h2-5,8-9,18H,6-7,10-11H2,1H3,(H2,24,25,31)(H,26,28,29)
|
| Chemical Name |
1-(3-chloro-4-methylphenyl)-3-[[2-(2,6-dioxopiperidin-3-yl)-3-oxo-1H-isoindol-5-yl]methyl]urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
